The Zhitong Finance App learned that on June 10, CDE's official website showed that tetrastuzumab, jointly developed by Daiichi Sankyo and AstraZeneca (AZN.US), was included in the priority review. The single drug is suitable for treating locally advanced or metastatic HER2 positive adult gastric or gastroesophageal adenocarcinoma patients who have received a treatment plan in the past.

Zhitongcaijing · 2d ago
The Zhitong Finance App learned that on June 10, CDE's official website showed that tetrastuzumab, jointly developed by Daiichi Sankyo and AstraZeneca (AZN.US), was included in the priority review. The single drug is suitable for treating locally advanced or metastatic HER2 positive adult gastric or gastroesophageal adenocarcinoma patients who have received a treatment plan in the past.